BriaCell Therapeutics (CVE:BCT – Free Report) had its price objective cut by HC Wainwright from C$18.00 to C$15.00 in a research report report published on Thursday morning, BayStreet.CA reports.
BriaCell Therapeutics Trading Down 3.8 %
BCT stock opened at C$10.60 on Thursday. BriaCell Therapeutics has a 12-month low of C$3.50 and a 12-month high of C$15.75. The business’s 50-day moving average is C$10.60 and its 200 day moving average is C$10.60. The company has a current ratio of 129.63, a quick ratio of 128.68 and a debt-to-equity ratio of 0.05. The stock has a market cap of C$168.68 million and a price-to-earnings ratio of -28.19.
BriaCell Therapeutics Company Profile
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- Insider Buying Explained: What Investors Need to Know
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- 5 Top Rated Dividend Stocks to Consider
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- 3 Grocery Stocks That Are Proving They Are Still Essential
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.